Publications Office of the EU
Conclusion of a non-exclusive discount agreement pursuant to § 130a(8) SGB V on the active substance omalizumab, ATC R03DX05 (OBO) for the period 01.08.2024 - 31.07.2025 (plus extension option 1x12 months) - EU tenders
DisplayCustomHeader
MyPortal
Language Selector
English
BasketSummary
Procurement Detail Actions Portlet

Utilities

Procurement Detail Actions Portlet
OP Portal - Procurement - Details

This page contains content generated automatically to improve findability and accessibility

- indicates text translated automatically in your browsing language

Conclusion of a non-exclusive discount agreement pursuant to § 130a(8) SGB V on the active substance omalizumab, ATC R03DX05 (OBO) for the period 01.08.2024 - 31.07.2025 (plus extension option 1x12 months) Text automatically translated in your browsing language Automatically translated

Overview
  • Published
    18/06/2024
  • Today
    17/04/2025
  • Deadline
    05/06/2026
  • Opening of tenders
    05/06/2026
Status
Published
Type of contract
Supplies
Subject for Renewal
No
Buyer
DAK-Gesundheit
Place of performance
NUTS code: Multiple place of performance
Location of buyer
NUTS code: DE600 Hamburg
Business sector (Main CPV)
33600000 Pharmaceutical products
Total estimated contract value (excluding VAT)
1.00 EUR
Total final contract value (excluding VAT)
Not available
Procedure details
Tender reference number
1004386 - Omalizumab (OBO), ATC R03DX05
Description

Section 130a(8) SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount agreements for the medicinal products to be supplied at the expense of the statutory health insurance funds. With regard to the relevant statutory provisions on public procurement, a regular process of active substance-related, formal procurement procedures takes place in accordance with the regulations of Part 4 of the GWB by the DAK-Gesundheit. For medicinal products for the above-mentioned active substance, omalizumab, ATC R03DX05, to be specified by the tenderer in Annex 2 to the contract, DAK-Gesundheit intends to conclude drug discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new drug discount contracts. A discount agreement as part of the approval model for the above-mentioned active substance enters into force for the first time on 1 August 2024 and ends on 31 July 2025 (plus an extension option of 1x12 months). Irrespective of this, it ends automatically with the entry into force of the exclusive contract. Text automatically translated in your browsing language Automatically translated

Submission Method
Electronic via:
https://www.dtvp.de/Satellite/notice/CXP4YM5HJSE
Tenders may be submitted
Electronic submission: required
https://www.dtvp.de/Satellite/notice/CXP4YM5HJSE
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
Not available
Conditions for opening tenders (date)
05/06/2026 12:01
Place of performance
DE Deutschland
DE600 Hamburg
Any country
CPV code

33600000 - Pharmaceutical products

Award method
Not available
Estimated value
1.00 EUR
Final contracted value
Not available
Award of contract
Not available
Documents
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.